489 related articles for article (PubMed ID: 20413454)
1. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Whitfield LR; Porcari AR; Alvey C; Abel R; Bullen W; Hartman D
J Clin Pharmacol; 2011 Mar; 51(3):378-88. PubMed ID: 20413454
[TBL] [Abstract][Full Text] [Related]
2. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Goosen TC; Bauman JN; Davis JA; Yu C; Hurst SI; Williams JA; Loi CM
Drug Metab Dispos; 2007 Aug; 35(8):1315-24. PubMed ID: 17470524
[TBL] [Abstract][Full Text] [Related]
4. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
5. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
6. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
7. Effects of fibrates on metabolism of statins in human hepatocytes.
Prueksaritanont T; Tang C; Qiu Y; Mu L; Subramanian R; Lin JH
Drug Metab Dispos; 2002 Nov; 30(11):1280-7. PubMed ID: 12386136
[TBL] [Abstract][Full Text] [Related]
8. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
9. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD; Dane AL; Schneck DW; Warwick MJ
Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
[TBL] [Abstract][Full Text] [Related]
10. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS.
Hermann M; Christensen H; Reubsaet JL
Anal Bioanal Chem; 2005 Jul; 382(5):1242-9. PubMed ID: 15933849
[TBL] [Abstract][Full Text] [Related]
11. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction.
Stern RH; Gibson DM; Whitfield LR
Eur J Clin Pharmacol; 1998 Feb; 53(6):475-8. PubMed ID: 9551707
[TBL] [Abstract][Full Text] [Related]
12. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
13. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.
Narwal R; Akhlaghi F; Asberg A; Hermann M; Rosenbaum SE
Clin Pharmacokinet; 2010 Oct; 49(10):693-702. PubMed ID: 20818835
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Teng R; Mitchell PD; Butler KA
Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
[TBL] [Abstract][Full Text] [Related]
15. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
[TBL] [Abstract][Full Text] [Related]
16. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Shin J; Pauly DF; Pacanowski MA; Langaee T; Frye RF; Johnson JA
Pharmacotherapy; 2011 Oct; 31(10):942-50. PubMed ID: 21950641
[TBL] [Abstract][Full Text] [Related]
17. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
